The question came during a dinner conversation, a familiar one for an oncologist: “Is there an ‘everything’ test for cancer?” It’s a hopeful query, born of understandable anxiety, and one I’ve learned to answer with careful honesty. There isn’t. Despite the allure of a single screening that could detect all cancers early, the reality of cancer detection remains far more nuanced. The recent results of a large-scale trial, however, underscore just how challenging—and potentially misleading—the pursuit of such a test can be.
The promise of early detection is central to cancer care. For patients and their families, finding cancer at its earliest stages often translates to more treatment options and a greater chance of a cure. This hope fuels ongoing research and innovation, including the development of so-called “liquid biopsies” – blood tests designed to identify cancer signals circulating in the bloodstream. But a recent, highly anticipated trial involving one such test, developed by the American company Grail, has revealed a critical distinction: finding more cancers doesn’t automatically equate to saving more lives.
Grail’s Galleri test, marketed with a high price tag of $949, aims to detect a signal shared by over 50 types of cancer through the analysis of circulating DNA. The test boasts the ability to pinpoint the potential location of the cancer within the body. Its marketing even included a Super Bowl ad, a testament to the public’s desire for a simple solution. The company partnered with the UK’s National Health Service (NHS) to conduct a landmark clinical trial, enrolling 142,000 adults aged 50 to 77 between 2021 and 2023, to assess the test’s effectiveness in a real-world setting.
The trial, a randomized controlled study considered the gold standard in medical research, involved taking blood samples from participants over two years. Half of the participants received the Galleri test, and if a cancer signal was detected, they underwent further investigation. The other half continued with standard healthcare practices. The core question: would the blood test lead to earlier diagnoses and, reduce the number of people diagnosed with late-stage cancer?
The results, published recently, were not as conclusive as Grail had hoped. While the trial did show a reduction in stage IV cancer diagnoses, it did not meet its primary endpoint of reducing overall late-stage (stage III and IV) cancer diagnoses. This finding is significant because it highlights a crucial point often lost in discussions about cancer screening: detecting a cancer doesn’t always translate to improved outcomes. The BBC reported on the trial’s findings, noting the disappointment surrounding the results.
Grail responded by emphasizing “strong” results, citing a substantial reduction in stage IV diagnoses and an increased detection rate of cancers at earlier stages. However, this interpretation has been met with skepticism, and the company’s share price plummeted following the announcement. Investors are now scrutinizing the data and a potential class action lawsuit has been filed, according to Business Wire.
The Challenge of Early Detection
The pursuit of “moonshot” approaches to cancer is not new. Decades of research have led to significant advances in treatment, offering improved quality of life and extended survival for many patients. But the Galleri trial underscores a fundamental challenge in cancer screening: the difference between detecting a cancer and preventing a patient from dying from it.
Detecting a cancer at stage III, for example, doesn’t automatically guarantee a better outcome than detecting it at stage IV. Treatment may still be intensive and challenging, and survival isn’t always improved. Some cancers detected through screening may never have become life-threatening during a patient’s lifetime – a phenomenon particularly common in older adults. In these cases, the anxiety and potential side effects of treatment may outweigh any benefit.
What we have is a scenario I often encounter in my practice. An elderly patient might undergo a CT scan for an unrelated issue, like a fall, and a small, unhurried-growing cancer is discovered incidentally. Left alone, it might never cause symptoms, but the discovery inevitably leads to further testing and potentially aggressive interventions that can significantly impact their quality of life.
Circulating DNA: A Promising, But Imperfect, Tool
Despite the setbacks with the Galleri trial, circulating tumor DNA (ctDNA) analysis holds significant promise in specific contexts. Researchers at the Walter and Eliza Hall Institute in Australia, for example, are pioneering the use of ctDNA to guide treatment decisions for colon cancer patients, helping to determine whether chemotherapy is likely to be effective.
This targeted approach, focusing on patients already diagnosed with cancer, is different from the broad population screening attempted by Grail. In these cases, ctDNA analysis can provide valuable information about the tumor’s characteristics and help personalize treatment plans.
What Can You Do to Reduce Your Cancer Risk?
For now, the most effective approach to cancer prevention remains focused on lifestyle factors. Reducing consumption of ultra-processed foods, moderating alcohol intake, avoiding smoking, and engaging in regular physical activity are all evidence-based strategies for reducing cancer risk.
The quest for an “everything” test for cancer continues, but the recent experience with Galleri serves as a crucial reminder: the path to improving cancer outcomes is complex and requires a nuanced understanding of the benefits and limitations of new technologies. It’s a path built on rigorous research, careful interpretation of data, and a commitment to prioritizing patient well-being.
Disclaimer: This article provides general information about cancer screening and should not be considered medical advice. Please consult with your healthcare provider to discuss your individual risk factors and appropriate screening options.
The next steps for Grail involve further analysis of the NHS trial data and potential refinement of the Galleri test. The company is also exploring the use of ctDNA analysis in more targeted screening programs. The scientific community will be closely watching these developments as we continue to strive for more effective ways to detect and treat cancer.
What are your thoughts on cancer screening? Share your experiences and questions in the comments below.
